Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 2
2005 1
2006 2
2007 2
2008 1
2016 1
2019 1
2020 1
2021 4
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

16 results
Results by year
Filters applied: . Clear all
Page 1
Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment.
Wang HQ, Mulford IJ, Sharp F, Liang J, Kurtulus S, Trabucco G, Quinn DS, Longmire TA, Patel N, Patil R, Shirley MD, Chen Y, Wang H, Ruddy DA, Fabre C, Williams JA, Hammerman PS, Mataraza J, Platzer B, Halilovic E. Wang HQ, et al. Among authors: mataraza j. Cancer Res. 2021 Jun 1;81(11):3079-3091. doi: 10.1158/0008-5472.CAN-20-0189. Epub 2021 Jan 27. Cancer Res. 2021. PMID: 33504557
Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer.
Even C, Wang HM, Li SH, Ngan RK, Dechaphunkul A, Zhang L, Yen CJ, Chan PC, Chakrabandhu S, Ma BBY, Tanasanvimon S, Lee VHF, Lou PJ, Li Z, Spira AI, Sukari A, Guigay J, McCune S, Gonzalez-Maffe J, Szpakowski S, Yao Y, Liang H, Mataraza J, Séchaud R, Manenti L, Lim DW. Even C, et al. Among authors: mataraza j. Clin Cancer Res. 2021 Dec 1;27(23):6413-6423. doi: 10.1158/1078-0432.CCR-21-0822. Epub 2021 Aug 25. Clin Cancer Res. 2021. PMID: 34433653 Clinical Trial.
First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.
Piha-Paul SA, Geva R, Tan TJ, Lim DW, Hierro C, Doi T, Rahma O, Lesokhin A, Luke JJ, Otero J, Nardi L, Singh A, Xyrafas A, Chen X, Mataraza J, Bedard PL. Piha-Paul SA, et al. Among authors: mataraza j. J Immunother Cancer. 2021 Aug;9(8):e002863. doi: 10.1136/jitc-2021-002863. J Immunother Cancer. 2021. PMID: 34389618 Free PMC article. Clinical Trial.
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors.
Naing A, Gainor JF, Gelderblom H, Forde PM, Butler MO, Lin CC, Sharma S, Ochoa de Olza M, Varga A, Taylor M, Schellens JHM, Wu H, Sun H, Silva AP, Faris J, Mataraza J, Cameron S, Bauer TM. Naing A, et al. Among authors: mataraza j. J Immunother Cancer. 2020 Mar;8(1):e000530. doi: 10.1136/jitc-2020-000530. J Immunother Cancer. 2020. PMID: 32179633 Free PMC article. Clinical Trial.
Multiple proteins mediate IQGAP1-stimulated cell migration.
Mataraza JM, Li Z, Jeong HW, Brown MD, Sacks DB. Mataraza JM, et al. Cell Signal. 2007 Sep;19(9):1857-65. doi: 10.1016/j.cellsig.2007.04.011. Epub 2007 May 5. Cell Signal. 2007. PMID: 17544257 Free PMC article.
IQGAP1 promotes cell motility and invasion.
Mataraza JM, Briggs MW, Li Z, Entwistle A, Ridley AJ, Sacks DB. Mataraza JM, et al. J Biol Chem. 2003 Oct 17;278(42):41237-45. doi: 10.1074/jbc.M304838200. Epub 2003 Aug 4. J Biol Chem. 2003. PMID: 12900413 Free article.
Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018).
Berry S, Giraldo N, Nguyen P, Green B, Xu H, Ogurtsova A, Soni A, Succaria F, Wang D, Roberts C, Stein J, Engle E, Pardoll D, Anders R, Cottrell T, Taube JM, Tran B, Voskoboynik M, Kuo J, Bang YL, Chung HC, Ahn MJ, Kim SW, Perera A, Freeman D, Achour I, Faggioni R, Xiao F, Ferte C, Lemech C, Meric-Bernstam F, Werner T, Hodi S, Messersmith W, Lewis N, Talluto C, Dostalek M, Tao A, McWhirter S, Trujillo D, Luke J, Xu C, BoMarelli, Qi J, Qin G, Yu H, Jenkins M, Lo KM, Halle JP, Lan Y, Taylor M, Vogelzang N, Cohn A, Stepan D, Shumaker R, Dutcus C, Guo M, Schmidt E, Rasco D, Brose M, Vogelzang N, Di Simone C, Jain S, Richards D, Encarnacion C, Rasco D, Shumaker R, Dutcus C, Stepan D, Guo M, Schmidt E, Taylor M, Vogelzang N, Encarnacion C, Cohn A, Di Simone C, Rasco D, Richards D, Taylor M, Dutcus C, Stepan D, Shumaker R, Guo M, Schmidt E, Mier J, An J, Yang YY, Lee WH, Yang J, Kim JK, Kim HG, Paek SH, Lee JW, Woo J, Kim JB, Kwon H, Lim W, Paik NS, Kim YK, Moon BI, Janku F, Tan D, Martin-Liberal J, Takahashi S, Geva R, Gucalp A, Chen X, Subramanian K, Mataraza J, Wheler J, Bedard P. Berry S, et al. Among authors: mataraza j. J Immunother Cancer. 2019 Feb 13;7(1):46. doi: 10.1186/s40425-019-0519-y. J Immunother Cancer. 2019. PMID: 30760319 Free PMC article.
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer.
Kuemmel S, Campone M, Loirat D, Lopez RL, Beck JT, De Laurentiis M, Im SA, Kim SB, Kwong A, Steger GG, Adelantado EZ, Duhoux FP, Greil R, Kuter I, Lu YS, Tibau A, Özgüroğlu M, Scholz CW, Singer CF, Vega E, Wimberger P, Zamagni C, Couillebault XM, Fan L, Guerreiro N, Mataraza J, Sand-Dejmek J, Chan A. Kuemmel S, et al. Among authors: mataraza j. Clin Cancer Res. 2022 Jan 1;28(1):106-115. doi: 10.1158/1078-0432.CCR-20-3955. Epub 2021 Oct 6. Clin Cancer Res. 2022. PMID: 34615719 Clinical Trial.
16 results